Lipitor news from FierceBiotech
NewsReport: Pfizer makes counter-offer for Ranbaxy
Pfizer may be crashing Daiichi Sankyo's party. Business Standard is reporting that Pfizer is considering a counter-offer for Ranbaxy, India's largest drugmaker. The rumor comes on the heels of the Read more...
Pfizer gets new cancer team to advance key drugs
With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to Read more...
ALSO NOTED: ISTA announces positive data; Proteolix launches Phase II trial; and much more...
> If anyone doubted Andrew Witty's professed faith in emerging markets, those doubts can be put to rest. The incoming GlaxoSmithKline CEO lured Eli Lilly's Abbas Hussein to spearhead a new unit Read more...
Full speed ahead for Vytorin II at Merck, Schering
The disastrous results of the recent Vytorin study have apparently done nothing to blunt the appetites Read more...
Merck cautiously upbeat on cholesterol drug
Merck is looking to succeed where Pfizer so spectacularly failed. Merck presented positive Phase II data for its CTEP inhibitor Read more...
Pfizer's future rests with biotech
At this week’s Bear Stearns Healthcare Conference, Pfizer discussed its plans for the future with analysts. As we all know, Pfizer is facing a major loss of sales when its best-selling drug Read more...
ALSO NOTED: Cell Therapeutics to bypass interim analysis; Nabi reports NicVAX data; Chinese see value in scientific failure; an
> Cell Therapeutics has decided to bypass an interim analysis of its non-Hodglin's lymphoma drug candidate Pixantrone. Instead, researchers say they will conduct a full analysis after the trial Read more...
ALSO NOTED: Pfizer's Lipitor patent request rejected; Spherix sells InfoSpherix; and much more...
> Pfizer's request for a reissued Lipitor patent was stamped "Rejected" by the U.S. Patent and Trademark Office--but the decision is only preliminary, so the drug maker can still hope for extended Read more...
ALSO NOTED: Pfizer profit plummets; Orchestra kills HIV program; and much more...
> There's big trouble at Pfizer, where profit plunged 48 percent in the second quarter as new generics ate up market share and Lipitor sales floundered. Read more...
| Press ReleasesPRESS RELEASE: Spanish Appellate Court Rules in Pfizer’s Favor, Upholds Lipitor Patent Spanish Appellate Court Rules in Pfizer’s Favor, Upholds Lipitor Patent NEW YORK -- Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering Read more... PRESS RELEASE: Canadian Court Finds Infringement of Lipitor Crystal Form Patent Canadian Court Finds Infringement of Lipitor Crystal Form Patent NEW YORK -- Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s patent covering a crystalline Read more... PRESS RELEASE: Canadian Court Favors Ranbaxy, Dismisses Pfizer's Application on Atrovastatin Patent CANADIAN FEDERAL COURT FAVOURS RANBAXY DISMISSES PFIZER'S APPLICATION ON ATORVASTATIN PATENT CA 2,220,455 Gurgaon, Haryana, India, Princeton, New Jersey, USA - September 13, 2007 Ranbaxy Read more... |
Get more Lipitor coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets